For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
State Directed Payments redistribute money across states and supercharged growth
Differences in states’ use of SDPs cause an interstate redistribution of taxes as well. Because states are setting different levels of SDPs, spending varies…
Blog
How State Directed Payments turned Medicaid into an interstate transfer scheme
Medicaid’s financing rules have long allowed states to expand spending while shifting much of the cost to federal taxpayers. One of the most important…
Blog
Medicaid financing gimmickry – before and after the One Big Beautiful Bill
Medicaid was created in 1965 as a joint federal-state health insurance program for low-income individuals which targeted families with dependent children, the elderly, and…
Search Posts
National Review
The Return of the Cadillac Tax?
Like the phoenix, a key piece of the Affordable Care Act has risen from the ashes, resurrected, believe it or not, by the Republican Study…
Blog
Free the Economy podcast: Paying for organs with Pete Jaworski
In this week’s episode we cover the future of AI and employment, why we shouldn’t trust Chinese economic statistics, and how…
City Journal
A Solution in Search of a Problem
In his State of the Union address, President Biden touted the drug-price controls in his Inflation Reduction Act (IRA). Though the price controls have…
Blog
This week in ridiculous regulations: Taconite and lab fees
President Biden delivered his State of the Union address. Super Tuesday primaries all but settled this year’s presidential combatants. The FTC has a full…
National Review
Covid Vaccines: An Update on Balancing Risks and Benefits
A new large, multi-country study has confirmed what previous smaller studies found: Covid-19 vaccines have risks. In particular, the messenger RNA (mRNA) vaccines from Pfizer…
City Journal
Ignoring the Science
A new CDC study reports that the first updated Covid-19 vaccine—the bivalent vaccine approved in fall 2022—was about 50 percent effective in blocking infection over a…